Actinium president to discuss role of radiopharmaceuticals alpha particle SNMMI annual meeting -
Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ( "actinium" or " company "), a biopharmaceutical company developing innovative immunotherapies useful target for the treatment of advanced cancers, today announced that clinical president of Actinium Advisory Board Joseph Jurcic, MD will participate in an upcoming roundtable highlighting the role of radiopharmaceuticals alpha particles Actinium in the treatment of leukemia patients. The briefing will provide information on alpha particles radiopharmaceutical therapy and how these agents are used clinically and summarize the results of recent tests. The annual meeting will be held SNMMI Saturday, June 7 - Wednesday, June 11, 2014, in St. Louis Convention Center, St. Louis, MO
The panel schedule is as follows :.
Date: Tuesday, June 10, 2014
Time: 17h00-5: 30 PM CDT
Room: 241-242
Session Title: "Ac-225 and Bi-213 radioimmunoconjugate therapy of leukemia "as part of a panel discussion entitled" Alpha-particle Emitter therapy ".
"alpha emitters offer the possibility of more effective killing of tumor cells without the toxicity of intensive chemotherapy," said Dr. Jurcic. "We are studying Actimab-A in combination with low-dose chemotherapy in older AML patients who are unable to tolerate standard chemotherapy. This is a group whose prognosis is extremely poor and for which new treatments are absolutely necessary. Using a Actimab- ™ could avoid the toxicities associated with standard therapy. "
Actimab-has is a radiolabeled antibody being developed for newly diagnosed AML patients over 60, and is currently in a multicenter clinical trial phase 1/2 with Dr. Jurcic as principal investigator. Based immunotherapy alpha particles Actinium (APIT) platform, Actimab-a consists of the antibody bound to CD33 Lintuzumab payload actinium-225. Actimab-a has attracted the support of leading experts in the the most prestigious hospitals and treatment of high-volume cancer due to the potential of its safety profile and effectiveness and its potency, specificity and ease of use. clinical trials are conducted in facilities world class cancer such as Memorial Sloan Kettering cancer Center, Johns Hopkins Medicine, University of Pennsylvania Health System, Fred Hutchinson cancer Center and MD Anderson cancer Center. the Company expects the interim phase 1/2 clinical trial results in December 2014. Actimab candidates are in early development for other cancers.
Dr. Jurcic is director of hematological malignancies Section of Hematology / Oncology Division and professor of clinical medicine at Columbia University Medical Center in New York. He is a hematologist / oncologist, focusing on the treatment of acute and chronic leukemia, myeloproliferative neoplasms, and myelodysplastic syndrome. His research interests include acute myeloid leukemia, radioimmunotherapy with radioisotopes that emit alpha and beta particles, the monoclonal antibody therapy for leukemia, the development of new small molecule inhibitors for leukemia and the molecular monitoring of minimal residual disease . He received his medical degree from the University of Pennsylvania and completed his fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center. In addition to clinical advisory board Chairing Actinium, Dr. Jurcic is the principal investigator of Actimab-A Testing Company
The annual meeting will be held SNMMI Saturday, June 7 -. Wednesday, June 11 at 10:00 am CDT on the park in St. Louis, MO. The speech of Dr. Jurcic is Tuesday, June 10, from 5: 00-5: 30 PM CDT, as part of the Alpha-Particle Emitter Therapy Session running from 4: 30-6: 00 PM CDT in 241-242 rooms. The debate will be moderated by George Sgouros, PhD, Professor of Radiology, Oncology and Radiation Oncology, Director of the Radiopharmaceutical Dosimetry Section of the Division of Nuclear Medicine, Johns Hopkins University School of Medicine. SNMMI mission is to improve human health by advancing nuclear medicine, molecular imaging and radionuclide therapy. For more information, please visit snmmi.org.
EmoticonEmoticon